HNPOLY(SZ:300630) Xin Lang Cai Jing·2026-01-09 08:19Group 1 - The core issue revolves around the financial fraud committed by Puli Pharmaceutical, which led to its forced delisting due to severe violations of regulations [1][2][4] - The company inflated its revenue by 1.031 billion yuan and its profit by 695 million yuan during 2021 and 2022, representing over 30% of total disclosed revenue and 76.72% of total disclosed profit for those years [5][6] - The China Securities Regulatory Commission (CSRC) issued a penalty of 10 million yuan and mandated corrective actions, highlighting the serious nature of the violations [2][6] Group 2 - Despite the delisting, the company remains liable for civil compensation, and investors who purchased shares between April 26, 2022, and April 16, 2024, are eligible to file claims [2][6] - Ongoing legal proceedings are in place for investors to seek compensation for losses incurred due to the company's fraudulent activities [2][6]